Navigation Links
Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
Date:5/21/2009

ited States.

About Alzheimer's Disease

Alzheimer's disease is a progressive neurodegenerative condition that is the most common cause of dementia, accounting for 60 to 80 percent of cases(ii). Estimates show that 6-8 percent of people over age 65 are affected by Alzheimer's disease(iii), totaling approximately 5.3 million people in the United States alone(ii). Every 70 seconds, an American is developing Alzheimer's disease(ii), and it is the sixth-leading cause of death in the United States(ii). The direct and indirect health care costs associated with Alzheimer's disease and other dementias in the U.S. are estimated to be about $150 billion(ii). In 2005, the total cost worldwide of dementia, of which Alzheimer's disease is the most common cause, was estimated at $315.4 billion(iv). The burden to caregivers and health care costs can increase dramatically in the late stages of Alzheimer's disease, when patients cannot maintain independent function and are frequently bedridden(ii).

About Solanezumab

Alzheimer's disease theory suggests that amyloid beta clumps together and eventually kills brain cells. Solanezumab binds specifically to soluble amyloid beta and thereby may draw the peptide away from the brain through the blood. In short-term clinical studies, solanezumab appeared to have dose-dependent effects on amyloid beta in blood and cerebrospinal fluid. The clinical studies to date have been too short to evaluate any potential delay in the progress of Alzheimer's disease. To date, the only side effect experienced in clinical studies that appeared to be associated with solanezumab treatment has been mild chills consistent with an infusion reaction; other side effects reported in the Phase II study include nausea, vomiting, headache, back pain, and cough. For a more complete listing of potential side effects, prospective clinical trial participants should refer to the informed consent document.


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
2. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
3. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
4. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
5. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
8. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
9. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
10. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
11. Lilly and TransPharma Medical Announce Licensing and Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 Perrigo Company plc, a public limited ... (the " Company "), today announced that it is ... its new 1.30% Senior Notes due 2016 (the " 2016 ... due 2018 (the " 2018 Exchange Notes "), $800,000,000 of ... Exchange Notes ") and $400,00,000 of its new 5.30% Senior ...
(Date:9/2/2014)... 2, 2014  XBiotech announced today interim results ... in the US for its anti-cancer agent Xilonix™. ... therapy, is being evaluated in advanced colorectal cancer ... The primary endpoint of the study is overall ... a control population provided only palliative therapy for ...
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
Breaking Medicine Technology:Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... March 7, 2011 Ajinomoto Co., a leader ... safe, effective nutraceutical solutions, has announced that its ... federal trademark registration, (®), on the Principal Register ...  The trademark is the latest milestone for Capsiate ...
... 7, 2011 HGI Global Holdings, Inc., a leading ... today announced the appointment of Michael B. Petras, Jr. ... Mr. Petras, 43, joins HGI from GE Lighting, ... (NYSE: GE ) where he served as ...
Cached Medicine Technology:Ajinomoto Co.'s Capsiate Natura® Reaches New Milestone 2Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader 2Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader 3
(Date:9/2/2014)... September 02, 2014 The Wm. Jennings Bryan ... and public town hall meeting for Veterans and their families ... the outreach fair to provide Veterans with valuable healthcare and ... town hall will provide a forum where we can gather ... , The outreach fair will be held 4:45 p.m. to ...
(Date:9/2/2014)... Essen, Germany, September 2, 2014 In a ... Germany, researchers found that mild cognitive impairment (MCI) ... diabetes mellitus type 2. Interestingly, this strong association ... whereas in older participants (66-80 years) the association ... Journal of Alzheimer,s Disease . , The concept ...
(Date:9/2/2014)... Operators in the Community Services ... annually, arranging care and counsel for those in need. ... expected to derive $39.4 billion in revenue, which includes ... Over the five years through 2014-15, the subdivision is ... including growth of 4.1% in 2014-15. , As the ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... device intended to help with weight loss by blocking a ... expectations in a trial among obese patients. Using electric ... brain and stomach, researchers hoped to suppress feelings of hunger. ... "A device that safely blocks the nerve that connects ...
(Date:9/2/2014)... locations with less intensive (and expensive) practice patterns appear ... spare patients unnecessary and excessive medical care, according to ... , "Growing concern about the costs and harms of ... to avoid the provision of unnecessary care," said lead ... The Dartmouth Institute for Health Policy & Clinical ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2
... within the Academy of Finland,s Research Programme on Substance Use ... aid in smoking reduction therapy. The new drug slows down ... down their smoking. Nicotine is absorbed rapidly through the ... from where it quickly passes through the body and into ...
... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... in a large hospital, more patients died, a new study ... of nursing shortages and cost-cutting, in that the focus should ... the research, appearing in the March 17 issue of the ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... (March 16, 2011) -- On March 28, leading experts ... Congress on Interventional Therapies for Type 2 Diabetes to ... treatment option. The three-day meeting, hosted by NewYork-Presbyterian Hospital/Weill ... together physicians, scientists and policymakers representing 60 countries. The ...
... trial using an all-natural lozenge to treat dry mouth, a ... way at Georgia Health Sciences University College of Dental Medicine. ... closed the faucet, and we want to turn that faucet ... and co-investigator of the study. "The cells and glands that ...
... Young adults are more likely to be heavy drinkers if they ... also had to cope with stressful life events, a new study ... women and 140 men in Germany who were asked about when ... the previous three years, what daily hassles they might have had ...
Cached Medicine News:Health News:New targeted drug helps smokers stub it out 2Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Diabetes Surgery 2nd World Congress 2Health News:Diabetes Surgery 2nd World Congress 3Health News:Diabetes Surgery 2nd World Congress 4Health News:Diabetes Surgery 2nd World Congress 5Health News:Clinical trial for dry mouth funded by international oral care award 2Health News:Drinking Behavior May Be Tied to Early Alcohol Use 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: